Study highlights pharmacovigilance challenges in CAR T-cell therapies, suggests specific assessment criteria
Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the Paul-Ehrlich-Institut highlights the challenges ...
Jan 24, 2025
0
23









